RedHill Biopharma Accelerates RHB104 Phase III Study in Crohns Disease with TopLine Results Expected Mid2018

RedHill has curtailed the target sample size in the ongoing first Phase III study with RHB104 for Crohns disease MAP US from 410 to approximately 325 subjects of which 322 have been enrolled to date while maintaining statistical power of over 80 with a tre...